Compare OZ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | KZIA |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.7M | 186.7M |
| IPO Year | 2020 | 2002 |
| Metric | OZ | KZIA |
|---|---|---|
| Price | $36.65 | $7.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 27.7K | ★ 229.9K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,187,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | N/A |
| 52 Week Low | $35.42 | $4.86 |
| 52 Week High | $69.00 | $17.40 |
| Indicator | OZ | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 37.13 |
| Support Level | $35.42 | $6.72 |
| Resistance Level | $48.00 | $8.18 |
| Average True Range (ATR) | 1.40 | 0.68 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 13.78 | 40.26 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.